A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study To Evaluate The Efficacy, Safety And Pharmacokinetics Of A Higher Dose Of Ocrelizumab In Adults With Relapsing Multiple Sclerosis
Posted Date: Oct 29, 2020
- Investigator: Lawrence Goldstick
- Specialties: Multiple Sclerosis, Neurology
- Type of Study: Drug
A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS
Criteria:
Patients With Relapsing Multiple Sclerosis Who Have Never Used Ocrelizumab
Keywords:
Ocrelizumab, Ocrevus, Multiple Sclerosis
For More Information:
Mikayla Hoeferlin
937-535-5012
hoefermj@ucmail.uc.edu